Patients

We are committed to developing transformative cell therapies to improve outcomes for patients with solid tumors.

Clinical Trials

We are motivated by our mission to develop curative therapies for solid tumor cancers. Testing our therapeutics for safety and efficacy in clinical trials depends on the participation of patients and their families. We are inspired by their courage in their fight against cancer and grateful for their choice to join us on this journey.

Triple-Negative Breast Cancer (TNBC)

TNBC is an aggressive cancer that metastasizes early and has few targeted therapies. The subtype accounts for an estimated 10 to 15 percent of invasive breast cancers and typically affects younger women.

 

LYL797 is a ROR1-targeted CAR T-cell therapy designed to overcome T-cell exhaustion and promote durable stemness. It incorporates Lyell’s novel genetic and epigenetic reprogramming technologies, Gen-R and Epi-R.

We are recruiting patients for this Phase 1 study to evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory TNBC or non-small cell lung cancer (NSCLC). For more information on this clinical trial, visit ClinicalTrials.gov or email clinicaltrials@lyell.com.

Non-Small Cell Lung Cancer (NSCLC)

NSCLC is a common lung cancer affecting large cells of the lungs. Despite recent treatment advances, NSCLC continues to have a low five-year survival rate.

 

LYL797 is a ROR1-targeted CAR T-cell therapy designed to overcome T-cell exhaustion and promote durable stemness. It incorporates Lyell’s novel genetic and epigenetic reprogramming technologies, Gen-R and Epi-R.

We are recruiting patients with NSCLC for the expansion portion of this Phase 1 study to evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory NSCLC or triple-negative breast cancer (TNBC). For more information on this clinical trial, visit ClinicalTrials.gov or email clinicaltrials@lyell.com.

Synovial Sarcoma (SS)

SS is a rare yet highly malignant tumor occurring in soft tissue. It is more common in adolescents and young adults than in older individuals. Patients often develop metastases, particularly to the lungs.

 

LYL132 is an NY-ESO-1-targeted TCR therapy that incorporates Epi-R, our novel epigenetic reprogramming technology designed to create populations of T cells with properties of durable stemness.

Our collaborators at GSK are recruiting patients for this study that will evaluate the safety and efficacy of LYL132 for patients with NY-ESO-1-positive advanced SS or myxoid/round cell liposarcoma (MRCLS). For more information on this clinical trial, visit ClinicalTrials.gov or email GSKClinicalSupportHD@gsk.com.

Myxoid/Round Cell Liposarcoma (MRCLS)

MRCLS is a type of liposarcoma, a rare soft connective tissue tumor that grows in cells that store fat in the body, typically in the arms and legs. MRCLS is one of the most common types of liposarcoma and makes up approximately 30% of all cases.

 

LYL132 is an NY-ESO-1-targeted TCR therapy that incorporates Epi-R, our novel epigenetic reprogramming technology designed to create populations of T cells with properties of durable stemness.

Our collaborators at GSK are recruiting patients for this study that will evaluate the safety and efficacy of LYL132 for patients with NY-ESO-1-positive MRCLS or advanced synovial sarcoma (SS). For more information on this clinical trial, visit ClinicalTrials.gov or email GSKClinicalSupportHD@gsk.com.